Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab + trastuzumab versus pertuzumab + trastuzumab + metronomic cyclophosphamide in elderly HER2-positive metastatic breast cancer
2011-006342-32Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Feb 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pertuzumab, trastuzumab, cyclophosphamide, trastuzumab emtansine in breast cancer, sponsored by European Organisation for Research and Treatment of Cancer. Started Feb 2013; status: completed.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-006342-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006342-32.